Associated Papers
Role of silent mutations in KRAS -mutant tumors.
Lu J et al.
Chinese Medical Journal, 2025
The theory of massively repeated evolution and full identifications of cancer-driving nucleotides (CDNs).
Zhang L et al.
Elife, 2024
39688960 (PubMed )
Supplement: elife-99340-supp1.xlsx › Synonymous_high_hits.gnomad
Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma.
Affinito O et al.
Cancer Cell International, 2022
35996174 (PubMed )
Supplement: 12935_2022_2680_MOESM5_ESM.xlsx › Stage1
Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
Poulsen TS et al.
Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2021
BRAF and RAS mutations in follicular variants of papillary thyroid carcinoma.
Park JY et al.
Endocrine Pathology, 2013
Clinical Implication of KRAS Mutation Variants in Patients With Resected Colon Cancer.
Baek JH et al.
Cancer Diagnosis & Prognosis, 0
Select a paper to view details